In Part 2, we speak with Prof. Arun Sanyal (Virginia Commonwealth University, Richmond, VA, USA) about the interim analysis from the ICONA trial (NCT04052516) which is designed to investigate icosabutate as a potential therapeutic approach to address liver- and cardiovascular-related morbidity and mortality in patients with NASH.
His abstract entitled ‘Icosabutate, a novel structurally engineered fatty acid, significantly reduces relevant markers of NASH and fibrosis in 16 weeks: interim analysis results of the ICONA trial’ was presented at the International Liver Congress (ILC) 2021, 23-26 June.
Please view Part 1 for information on the mechanism of action of icosabutate.
Disclosures: Prof Arun Sanyal has acted as an advisor/board member for Gilead; a consultant for 89 BIO, Affimune, Albireo, Allergan, AMRA, Ardelyx, BASF, Birdrock, Boehringer Ingelheim, Bristol Myers Squibb, Chemomab, Conatus, Durect, Echosans, Enyo, Fractyl, Galectin, General Electric, Genfit, Gilead Hemoshear, Immuron, Indalo, Intercept, Janssen, Lilly, Malinckrodt, Merck, Nimbus, Novartis, Northsea, Novo Nordisk, Perspectum, Pfizer, Poxel, Salix, Sanofi, Second Genome, Servier, Takeda, Terns, Teva, Zydus; received grant/research support from Bristol-Myers Squibb, Conatus, Echosans, Galectin, Gilead, Lilly, Malinckrodt, Merck, Novartis, Novo Nordisk, Fractyl, Madrigal, Inventiva, Covance and Sequana; has stockholder/ownership interest (excluding diversified mutual funds) in Akarna, Durect, Exhalenz, Genfit, Hemoshear, Indalo, Tiziana; is PI for an ongoing trial sponsored by Genfit; has provided advice (no remuneration) to BASF, Galectin, Immuron and has received Royalties from Elsevier and UpToDate.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
Share this Video
Related Videos In Liver Disorders
Luca Valenti, NAFLD Summit 2021: The Latest Advances in NAFLD
TouchENDOCRINOLOGY joins Prof Luca Valenti (University of Milan, Italy) at the Digital NAFLD Summit 2021 to discuss his hopes for the conference and the most exciting new developments in the field of non-alcoholic fatty liver disease (NAFLD). Questions Could you give us an overview of the clinical spectrum of non-alcoholic fatty liver disease (NAFLD) and […]
Rohit Loomba, EASL ILC 2021: Pemafibrate Phase 2 Results in NAFLD
We continue our discussion with Prof. Rohit Loomba (University of California, San Diego, CA, USA) by exploring the results for the phase 2 study investigating pemafibrate in NAFLD. Part 1 of our video interview can be found here. His presentation entitled ‘Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARM alpha), improves liver stiffness […]
Rohit Loomba, EASL ILC 2021: Rationale for Pemafibrate in NAFLD
It was a pleasure to speak with Prof. Rohit Loomba (University of California, San Diego, CA, USA) about the rationale for the use of the novel SPPARM inhibitor, pemafibrate, in the treatment of NAFLD. Part 2 of our discussion can be found here. His presentation entitled ‘Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!